These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 4388368)

  • 1. The pharmacology of parkinsonism (a review).
    Klawans HL
    Dis Nerv Syst; 1968 Dec; 29(12):805-16. PubMed ID: 4388368
    [No Abstract]   [Full Text] [Related]  

  • 2. Medical management of parkinsonian syndrome.
    Sytkowski AJ; Chun WH; Wang RI
    Wis Med J; 1969 May; 68(5):197-200. PubMed ID: 4389034
    [No Abstract]   [Full Text] [Related]  

  • 3. The pharmacotherapy of Parkinsonism.
    Pinder RM
    Prog Med Chem; 1972; 9(2):192-274. PubMed ID: 4147180
    [No Abstract]   [Full Text] [Related]  

  • 4. [Treatment of parkinsonism with the Bulgarian preparations INHA-17 and bellazon].
    Stoliarova LG
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1966; 66(5):698-703. PubMed ID: 4873628
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical effectiveness of anti-motion-sickness drugs. Computer review of the literature.
    Wood CD; Kennedy RE; Graybiel A; Trumbull R; Wherry RJ
    JAMA; 1966 Dec; 198(11):1155-8. PubMed ID: 4380819
    [No Abstract]   [Full Text] [Related]  

  • 6. [Therapy of extrapyramidal-motor symptoms. Drug treatment].
    Hartmann-von Monakow K
    Bibl Psychiatr Neurol; 1969; 139():697-704. PubMed ID: 5406928
    [No Abstract]   [Full Text] [Related]  

  • 7. L-Dopa and Parkinsonism.
    Calne DB; Sandler M
    Nature; 1970 Apr; 226(5240):21-4. PubMed ID: 4907560
    [No Abstract]   [Full Text] [Related]  

  • 8. [Trial use of L-dopa associated with a dopa-decarboxylase inhibitor in Parkinson's syndrome].
    Carotti A; Tomassetti G; Lucciarini L; Barone G; Mugnai A
    Clin Ter; 1974 Jul; 70(1):9-15. PubMed ID: 4153252
    [No Abstract]   [Full Text] [Related]  

  • 9. [Drug therapy of Parkinson disease and parkinson disease-like symptoms].
    Kehr W
    Arzneimittelforschung; 1981; Suppl 27():26-33. PubMed ID: 7197938
    [No Abstract]   [Full Text] [Related]  

  • 10. The antiparkinsonian activity of monoamine oxidase inhibitors and other agents in rats and mice.
    Dandiya PC; Bhargava LP
    Arch Int Pharmacodyn Ther; 1968 Nov; 176(1):157-67. PubMed ID: 5709781
    [No Abstract]   [Full Text] [Related]  

  • 11. Effects of L-DOPA on pharmacological parkinsonism.
    Bruno A; Bruno SC
    Acta Psychiatr Scand; 1966; 42(3):264-71. PubMed ID: 5335155
    [No Abstract]   [Full Text] [Related]  

  • 12. [On the affinity of atropine derivatives for acetylcholine and histamine receptors in the guinea pig ileum].
    Bosse JA; Wassermann O
    Naunyn Schmiedebergs Arch Exp Pathol Pharmakol; 1967; 259(1):34-44. PubMed ID: 4385951
    [No Abstract]   [Full Text] [Related]  

  • 13. Parkinsonism.
    Shimomura SK
    J Am Pharm Assoc; 1972 Jan; 12(1):29-36. PubMed ID: 4399879
    [No Abstract]   [Full Text] [Related]  

  • 14. [Attempt at treating parkinsonism with L-dopa and Artane].
    Stelmasiak Z; Lackowska H; Maksymowicz B
    Pol Tyg Lek; 1971 Aug; 26(34):1325-6. PubMed ID: 5110789
    [No Abstract]   [Full Text] [Related]  

  • 15. [Transmethylating activity in vitro in patients with parkinsonism before and after treatment with L-dopa].
    Carella A; Valenti P; Buscaino GA
    Acta Neurol (Napoli); 1971; 26(1):41-5. PubMed ID: 5553940
    [No Abstract]   [Full Text] [Related]  

  • 16. Uptake of exogenous catecholamines by monoamine-containing neurons of the central nervous system: uptake of catecholamines by arcuato-infundibular neurons.
    Lichtensteiger W; Langemann H
    J Pharmacol Exp Ther; 1966 Mar; 151(3):400-8. PubMed ID: 5938477
    [No Abstract]   [Full Text] [Related]  

  • 17. Effect of reserpine and other drugs on the monoamine metabolism with special reference to the CNS.
    Andén NE
    Ann Med Exp Biol Fenn; 1968; 46(3):361-6. PubMed ID: 4308996
    [No Abstract]   [Full Text] [Related]  

  • 18. [Drug-induced Parkinson's syndrome].
    Degkwitz R
    Dtsch Med Wochenschr; 1972 Jun; 97(22):882. PubMed ID: 5032182
    [No Abstract]   [Full Text] [Related]  

  • 19. [l-dopa treatment of Parkinson's syndrome and mechanism of action of neuroleptics].
    Degkwitz R
    Med Klin; 1969 Aug; 64(33):1451-6. PubMed ID: 4896563
    [No Abstract]   [Full Text] [Related]  

  • 20. [Factors which influence infavourably l-dopa treatment].
    Presthus J
    Tidsskr Nor Laegeforen; 1973 Oct; 93(28):2115-6. PubMed ID: 4590071
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.